Dicerna Pharmaceuticals Inc (DRNA) Chief Scientific Ofr. ...
- By insider
Chief Scientific Ofr., EVP R&D of Dicerna Pharmaceuticals Inc (30-Year Financial, Insider Trades) Bob D Brown (insider trades) sold 21,630 shares of DRNA on 01/25/2021 at an average price of $25 a share. The total sale was $540,750.
Dicerna Pharmaceuticals Inc is a biopharmaceutical company. It develops ribonucleic acid interference-based pharmaceuticals for treating diseases involving liver, including rare, chronic liver, cardiovascular and viral infections. Dicerna Pharmaceuticals Inc has a market cap of $1.85 billion; its shares were traded at around $24.620000 with and P/S ratio of 13.87. Dicerna Pharmaceuticals Inc had annual average EBITDA growth of 12.40% over the past five years. GuruFocus has detected 3 severe warning signs with Dicerna Pharmaceuticals Inc. .
Directors and Officers Recent Trades:
Chief Scientific Ofr., EVP R&D Bob D Brown sold 21,630 shares of DRNA stock on 01/25/2021 at the average price of $25. The price of the stock has decreased by 1.52% since.
Chief Human Resources Officer Regina M. Paglia sold 6,326 shares of DRNA stock on 01/25/2021 at the average price of $25. The price of the stock has decreased by 1.52% since.
COO & EVP James B Weissman sold 5,808 shares of DRNA stock on 01/12/2021 at the average price of $24.08. The price of the stock has increased by 2.24% since.
See Remarks Bob D Brown sold 5,808 shares of DRNA stock on 01/12/2021 at the average price of $24.07. The price of the stock has increased by 2.29% since.
COO & EVP James B Weissman sold 3,800 shares of DRNA stock on 01/11/2021 at the average price of $23.99. The price of the stock has increased by 2.63% since.
For the complete insider trading history of DRNA, click here
.This article first appeared on GuruFocus.
